RVPH250417P5000
- 3.58
- 0.000.00%
Reviva Pharmaceuticals Newsroom
Reviva Pharmaceuticals: Promising Schizophrenia Treatment Drives Buy Rating
Roth MKM Reaffirms Their Buy Rating on Reviva Pharmaceuticals Holdings (RVPH)
Reviva Pharmaceuticals Analyst Ratings
H.C. Wainwright Maintains Reviva Pharmaceuticals(RVPH.US) With Buy Rating, Cuts Target Price to $7
Maxim Group Initiates Reviva Pharmaceuticals(RVPH.US) With Buy Rating, Announces Target Price $7
Maxim Group Upgrades Reviva Pharmaceuticals(RVPH.US) to Buy Rating, Announces Target Price $7
Reviva Pharmaceuticals Upgraded to Buy From Hold at Maxim
Reviva Pharmaceuticals Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Globus Medical (GMED) and Reviva Pharmaceuticals Holdings (RVPH)
Roth MKM Initiates Reviva Pharmaceuticals(RVPH.US) With Buy Rating, Announces Target Price $7
Maxim Group Maintains Reviva Pharmaceuticals(RVPH.US) With Hold Rating
Reviva Pharmaceuticals Analyst Ratings
Reviva Pharm Holdings Is Maintained at Buy by D. Boral Capital
Reviva Pharm Holdings Price Target Maintained With a $15.00/Share by D. Boral Capital
Reviva Pharmaceuticals Analyst Ratings
D. Boral Capital Maintains Buy on Reviva Pharmaceuticals, Maintains $15 Price Target
Maxim Group Maintains Reviva Pharmaceuticals(RVPH.US) With Hold Rating
Maxim Group Keeps Their Hold Rating on Reviva Pharmaceuticals Holdings (RVPH)
Reviva Pharm Holdings Price Target Announced at $15.00/Share by EF Hutton
Reviva Pharm Holdings Initiated at Buy by EF Hutton